A Phase 1 interventional study of Futibatinib and Binimetinib in Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer and KRAS Gene Mutation, sponsored by Taiho Oncology, Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Otsuka Holdings Co., Ltd..
Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2021, is one of 4 in phase 1, and was the 7th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →3 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Taiho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Taiho Pharmaceutical Co., Ltd. · Sites in United States, Australia, Japan and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 2
First in 1999; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 128 across the 11 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Taiho Oncology, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
2 of the studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05973773Phase 3Taiho Oncology, Inc.REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | 2027-05-27 |
| NCT04999761Taiho Pharmaceutical Co., Ltd.AB122 Platform Study | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
This is an open-label, nonrandomized, uncontrolled Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) of futibatinib in combination with binimetinib and to explore the preliminary antitumor activity of futibatinib in combination with binimetinib in patients with advanced KRASmt tumors.
The study will consist of two parts:
Patients will receive study treatment until progressive disease or any other discontinuation or withdrawal criterion is met.
No patients were enrolled in Phase 2 as the Sponsor decided to not proceed with the dose expansion Phase 2 part of the TAS-120-204 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease. Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC
Drug: Futibatinib and Binimetinib
Drug pages: Futibatinib · Binimetinib
Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
Recommended Phase 2 Dose (RP2D) in Part 1
Determine RP2D of futibatinib in combination with binimetinib based on Dose Limiting Toxicities
Time frame: 12 months
Objective Response Rate (ORR) in Part 2
proportion of patients who have achieved a PR or complete response (CR) according to RECIST 1.1.
Time frame: approximately 24 months
Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of futibatinib, binimetinib, and AR00426032
Plasma concentrations of futibatinib, binimetinib, and AR00426032
Time frame: approximately 24 months
PK: Area under the plasma concentration-time curve (AUC) of futibatinib, binimetinib, and AR00426032
Plasma concentrations of futibatinib, binimetinib, and AR00426032
Time frame: approximately 24 months
PK: Time to reach maximum plasma concentration (Tmax) of futibatinib, binimetinib, and AR00426032
Plasma concentrations of futibatinib, binimetinib, and AR00426032
Time frame: approximately 24 months
PK: Terminal elimination half-life (T1/2) of futibatinib, binimetinib, and AR00426032
Plasma concentrations of futibatinib, binimetinib, and AR00426032
Time frame: approximately 24 months
PK: Minimum plasma concentration before administration (Cmin) of futibatinib, binimetinib, and AR00426032
Plasma concentrations of futibatinib, binimetinib, and AR00426032
Time frame: approximately 24 months
PK: Accumulation ratio of Cmax and AUC (R) of futibatinib, binimetinib, and AR00426032
Plasma concentrations of futibatinib, binimetinib, and AR00426032
Time frame: approximately 24 months
Duration of response (DOR)
DOR is defined as the length of time between first response and the date of objectively documented progression of disease or death
Time frame: approximately 24 months
Progression-free survival (PFS)
PFS is defined as the time from date of first dose to objectively documented progression of disease or death
Time frame: approximately 24 months
Disease control rate (DCR) at 24 months
DCR is defined as the percentage of patients who have achieved a CR, PR, or SD.
Time frame: approximately 24 months
Number of patients with treatment-emergent adverse events as assessed by CTCAE v5.0
Evaluate safety and tolerability of futibatinib in combination with binimetinib based on treatment-emergent adverse events per CTCAE v5.0(including serious adverse events),clinical laboratory parameters, ECGs, and vital signs
Time frame: Approximately 24 months
Ran from Sep 2021 to primary completion in Jun 2023, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Futibatinib · Binimetinib
Carcinoma, Non-Small-Cell Lung →